Related Experiment Video

Updated: Jun 23, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Drug antagonism and single-agent dominance result from differences in death kinetics

Ryan Richards1, Hannah R Schwartz1, Megan E Honeywell1

  • 1Program in Systems Biology (PSB), University of Massachusetts Medical School, Worcester, MA, USA.

Nature Chemical Biology
|April 7, 2020
PubMed

Insights

Cancer drug combinations can cancel each other out, a phenomenon called antagonism. This study reveals that the timing of cell death pathways dictates this antagonistic effect, offering new insights into combination cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Cancer therapy frequently employs drug combinations.
  • Research has primarily focused on synergistic drug interactions, neglecting antagonistic effects.
  • Understanding drug antagonism is crucial for optimizing cancer treatment strategies.

Purpose of the Study:

  • To investigate antagonistic drug-drug interactions in cancer therapy.
  • To identify common features and mechanisms underlying drug antagonism.
  • To explore the role of regulated cell death pathways in drug antagonism.

Main Methods:

  • Screened all pairwise combinations of drugs that activate regulated cell death.
  • Analyzed combinations for antagonistic interactions, specifically 'single-agent dominance'.
  • Investigated the mechanistic basis of antagonism between parthanatotic and apoptotic agents, focusing on Poly(ADP-ribose) polymerase 1 (PARP1) activity.

Main Results:

  • The screened network showed a significant enrichment for antagonism, particularly 'single-agent dominance'.
  • 'Single-agent dominance' occurs when a combination's effect mimics a single drug, driven by differences in cell death onset.
  • Parthanatotic agents dominated apoptotic agents due to conflicting Poly(ADP-ribose) polymerase 1 (PARP1) utilization, demonstrating pathway crosstalk.

Conclusions:

  • Drug antagonism in cancer therapy is influenced by the kinetics of cell death pathways.
  • Differences in drug-induced cell death timing predict antagonistic interactions.
  • Inhibitory crosstalk between cell death pathways is a key mechanism driving drug antagonism.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Comprehensive Analysis of Drug Response using the FLICK Assay09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...